Safety and efficacy of long-term treatment with different ASA forms in patients with stable IHD and a high risk for development of gastropathy by data from a cross-sectionals study

Aim. To study indexes of efficacy, safety and compliance for different ASA forms (Aspirin-Cardio, Cardiomagnyl, Thrombo ASS) used in stable IHD. Materials and methods. An open, cross-sectional study compared three groups of patients consisting of 200 patients each who had stable IHD and a high risk of gastrointestinal disorders and who received a long-term antiaggregant monotherapy with one of ASA drugs (group 1, Aspirin Cardio; group 2, Thrombo ASS; group 3, Cardiomagnyl). Efficacy, safety and compliance with the treatment were evaluated using standard tests and analogue scales; dyspepsia symptoms were evaluated using a special, additionally developed questionnaire. Results. The Aspirin-Cardio treatment reduced the mean score of GI symptom severity from the questionnaire (1.4-1.6 times, р=0.001), requirement for proton pump inhibitors (р=0.002) and endoscopy during the ASA treatment (р=0.001), and proportion of non-compliant patients according to the Morisky test (р=0.0001). The ROC analysis showed that the mean score of GI symptom questionnaire >3 predicted non-compliance or insufficient compliance with a diagnostic sensitivity of 58.9% and specificity of 56.3% (р=0.002), which makes this value a threshold for considering a modification of the treatment. Conclusion. Aspirin-Cardio is characterized by better safety in respect of GI symptoms and better compliance with the treatment during long-term prophylactic therapy. The proposed questionnaire for evaluation of GI symptoms can be used for specifying indications and modifying the treatment tactics.

препараты ацетилсалициловой кислоты, безопасность, комплаентность, желудочно-кишечные расстройства, acetylsalicylic acid preparations, safety, copmliance, gastrointestinal disorders

1. Шальнова С.А., Деев А.Д., Оганов Р.Г. Факторы, влияющие на смертность от сердечно-сосудистых заболеваний в российской популяции. Кардиоваскулярная терапия и профилактика. 2005; 4 (1): 4-9 [Shal'nova S. A., Deev A. D., Oganov R. G. Faktory', vliyayushhie na smertnost' ot serdechno-sosudisty'x zabolevanij v rossijskoj populyaczii. Kardiovaskulyarnaya terapiya i profilaktika. 2005; 4 (1): 4-9].

2. Лепахин В.К. Фармакология и лекарственная терапия. М.: Эксмо; 2009. 464 с [Lepaxin V. K. Farmakologiya i lekarstvennaya terapiya. M.: E'ksmo; 2009. 464 s].

3. Косарев В.В., Бабанов С.А., Вербовой А. Ф. Справочник клинического фармаколога. Ростов-на-Дону: Феникс; 2011. 477 с [Kosarev V. V., Babanov S. A., Verbovoj A. F. Spravochnik klini-cheskogo farmakologa. Rostov-na-Donu: Feniks; 2011. 477 s].

4. Antithrombotic Trialists' Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324 (7329): 71-86.

5. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet. 1988; 2 (8607): 349-60.

6. Говорин А.В., Филёв А.П. Ацетилсалициловая кислота в профилактике атеротромбоза. Рациональная фармакотерапия в кардиологии. 2012; 8 (2): 237-41 [Govorin A. V., Filyov A. P. Aczetilsali czilovaya kislota v profilaktike aterotromboza. Raczional'naya far-makoterapiya v kardiologii. 2012; 8 (2): 237-41].

7. Ridker P.M., Manson J.E., Gaziano J.M., Buring J.E., Hennekens C.H. Low-dose aspirin therapy for chronic stable angina. A randomized, placebo-controlled clinical trial. Ann Intern Med. 1991; 114 (10): 835-9.

8. Juul-Möller S., Edvardsson N., Jahnmatz B., Rosén A., Sorensen S., Omblus R. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet. 1992; 340 (8833): 1421-5.

9. Ежов М.В. Преимущества длительного применения клопидо-грела у больных ишемической болезнью сердца. РМЖ. 2009; 17 (18): 1140-3 [Ezhov M. V. Preimushhestva dlitel'nogo primen-eniya klopidogrela u bol'ny'x ishemicheskoj bolezn'yu serdcza. RMZh. 2009; 17 (18): 1140-3]. ОРИГИНАЛЬНЫЕ СТАТЬИ

10. Roffi M., Patrono C., Collet J.-P., Mueller C., Valgimigli M., Andreotti F. et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016; 37 (3): 267-315. DOI: 10.1093/eurheartj/ehv320.

11. ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). European Heart Journal. 2014; 35 (37): 2541-619. DOI: 10.1093/eurheartj/ehu278.

12. Hawkey C.J., Langman M.J.S. Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors. Gut. 2003; 52 (4): 600-8.

13. Яковенко Э.П., Иванов В.А., Яковенко А.В., Агафонова Н.А., Овчинникова Н.И., Алдиярова М.А. и др. Пептические язвы, патогенетические подходы к терапии. Фарматека. 2008; (13): 62-8 [Yakovenko E'. P., Ivanov V. A., Yakovenko A. V., Agafonova N. A., Ovchinnikova N. I., Aldiyarova M. A. i dr. Pepticheskie yazvy', pato-geneticheskie podxody' k terapii. Farmateka. 2008; (13): 62-8].

14. Takeuchi K. Pathogenesis of NSAID-induced gastric damage: importance of cyclooxygenase inhibition and gastric hypermotility. WorldJ Gastroenterol. 2012; 18 (18): 2147-60. DOI: 10.3748/wjg.v18.i18.2147.

15. Feldman M., editor. Sleisenger & Fortran's Gastrointestinal and Liver Disease: in 2 vol. 6th ed. Philadelphia: Saunders; 1998. 2046 p.

16. Karateev A.E., Nasonov E.L., Yakhno N.N., Ivashkin V.T., Chichasova N.V., Alekseeva L.I. et al. Clinical guidelines “Rational use of nonsteroidal anti-inflammatory drugs (NSAIDs) in clinical practice". Modern Rheumatology Journal. 2015; (1): 4. DOI: 10.14412/1996-7012-2 015-1-4-23.

17. Mallen S.R., Essex M.N., Zhang R. Gastrointestinal tolerability of NSAIDs in elderly patients: a pooled analysis of 21 randomized clinical trials with celecoxib and nonselective NSAIDs. Curr Med Res Opin. 2011; 27 (7): 1359-66. DOI: 10.1185/03007995.2011.5 81274.

18. Lanas A. A review of the gastrointestinal safety data - a gastroenterologist's perspective. Rheumatology (0xford). 2010; 49 Suppl 2: ii3-10.DOI: 10.1093/rheumatology/keq058.

19. Багликов А.Н., Рафальский В.В. Значение приверженности пациентов к лечению при длительном приеме ацетилсалициловой кислоты у пациентов, перенесших острый коронарный синдром: результаты исследования. Кардиология. 2012; 52 (9): 22-8 [Baglikov A. N., Rafal'skij V. V. Znachenie priverzhennosti paczientov k lecheniyu pri dlitel' nom prieme aczetilsaliczilovoj kisloty' u paczientov, perenesshix ostry'j koronarny'j sindrom: rezul'taty' issledovaniya. Kardiologiya. 2012; 52 (9): 22-8].

20. Rojas-Fernandez C.H., Kephart G.C., Sketris I.S., Kass K. Underuse of acetylsalicylic acid in individuals with myocardial infarction, ischemic heart disease or stroke: data from the 1995 population-based Nova Scotia Health Survey. CanJ Cardiol. 1999; 15 (3): 291-6.

21. Булахова Е.Ю., Кореннова О.Ю., Козырева В.А., Курочкина С.Д., Муротова С.А. Возможности снижения развития гастродуоденальных осложнений при длительном использовании препаратов ацетилсалициловой кислоты. Кардиоваскулярная терапия и профилактика. 2010; 9 (4): 41-4 [Bulaxova E.Yu., Korennova О.Yu., Kozy'reva V.A., Kurochkina S.D., Murotova S.A. Vozmozhnosti snizheniya razvitiya gastroduodenal'ny'x oslozhnenij pri dlitel'nom ispol'zovanii preparatov aczetilsaliczilovoj kisloty'. Kardiovaskulyarnaya terapiya i profilaktika. 2010; 9 (4): 41-4].

22. Каратеев А.Е. Шесть ножей в спину ингибиторам протонной помпы. Научно-практическая ревматология. 2013; 51 (3): 332-40 [Karateev A. E. Shest' nozhej v spinu ingibitoram protonnoj pompy'. Nauchno-prakticheskaya revmatologiya. 2013; 51 (3): 332-40].